Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Repertoire Immune Medicines to Present Data from Autologous T Cell Therapy PRIME IL-15 (RPTR-147) in Advanced or Metastatic Solid Tumor Cancers
April 9, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 9, 2021
Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced the presentation of translational data obtained from applying its proprietary antigen-specific TCR-MHC DECODE™ platform in its Phase 1 trial evaluating PRIME IL-15 (RPTR-147) in patients with advanced or metastatic solid tumor cancers. The data will be presented at the American Association of Cancer Research (AACR) Virtual Meeting Week 1, taking place April 10-15, 2021. PRIME IL-15, the company’s lead investigational therapy, is a novel non-genetically modified,
Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune E pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers
February 11, 2021 GMT
Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines (Photo: Business Wire)
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 11, 2021
Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced a research collaboration with Dana-Farber Cancer Institute to advance discovery and clinical development in human papillomavirus-positive (HPV+) oropharyngeal (head and neck) cancers. Through this collaboration, Dana-Farber and Repertoire aim to identify novel tumor antigen targets relevant to HPV+ head and neck tumors that will be used to inform the development of novel therapeutic candidates.